logo
logo

Deepcell Closes $20 Million Series A Round to Develop AI-Powered Capture of Cells for Precision Medicine

Dec 07, 2020•over 4 years ago

Amount Raised

$20 Million

Round Type

series a

Menlo Park

Description

Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced that it has closed its Series A round of financing with $20 million, led by Bow Capital and joined by Andreessen Horowitz, which led its $5 million seed round. The new funding will allow Deepcell to develop its microfluidics-based technology, continue building a cell morphology atlas of more than 400 million cells, and drive a hypothesis-free approach to cell classification and sorting.

Company Information

Company

Deepcell

Location

Menlo Park, California, United States

About

Deepcell is helping to advance precision medicine by combining advances in AI, cell classification and capture, and single-cell analysis to deliver novel insights through an unprecedented view of cell biology. Spun out of Stanford University in 2017, the company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features and sort them without inherent bias. The Deepcell platform maintains cell viability for downstream single-cell analysis and can be used to isolate virtually any type of cell, even those occurring at frequencies as low as one in a billion. The technology will initially be available as a service for use in translational research as well as diagnostics and therapeutic development. Deepcell is privately held and based in Menlo Park, CA. For more information, please visit deepcellbio.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech